Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

4,121 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy.
Nobuoka D, Yoshikawa T, Fujiwara T, Nakatsura T. Nobuoka D, et al. Among authors: fujiwara t. Hum Vaccin Immunother. 2013 Jun;9(6):1234-6. doi: 10.4161/hv.23990. Epub 2013 Feb 14. Hum Vaccin Immunother. 2013. PMID: 23411443 Free PMC article. Review.
Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Fujioka K, Takada Y, Uchida S, Onoda T, Orita K. Fujiwara T, et al. Biotherapy. 1991;3(3):203-9. doi: 10.1007/BF02171683. Biotherapy. 1991. PMID: 1854589
Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Uchida S, Fujioka K, Takada Y, Onoda T, Orita K. Fujiwara T, et al. Cancer Res. 1990 Nov 1;50(21):7003-7. Cancer Res. 1990. PMID: 2208166
Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
Fujiwara T, Sakagami K, Orita K. Fujiwara T, et al. J Cancer Res Clin Oncol. 1990;116(2):141-8. doi: 10.1007/BF01612668. J Cancer Res Clin Oncol. 1990. PMID: 2324156
Development of an interleukin-2 slow delivery system.
Matsuoka J, Sakagami K, Shiozaki S, Uchida S, Fujiwara T, Gohchi A, Orita K. Matsuoka J, et al. Among authors: fujiwara t. ASAIO Trans. 1988 Jul-Sep;34(3):729-31. ASAIO Trans. 1988. PMID: 3264177
Immunotherapy by a slow delivery system of interleukin-2 in mice models.
Matsuoka J, Sakagami K, Fujiwara T, Onoda T, Idani H, Gochi A, Orita K. Matsuoka J, et al. Among authors: fujiwara t. Acta Med Okayama. 1993 Apr;47(2):79-84. doi: 10.18926/AMO/31570. Acta Med Okayama. 1993. PMID: 8506753
[Recombinant virus-mediated transfer of the wild-type p53 gene is a potent therapeutic strategy for human cancer].
Fujiwara T, Kagawa S, Ogawa N, Yasuda T, Tanaka N, Orita K, Cai DW, Zhang WW, Roth JA. Fujiwara T, et al. Hum Cell. 1996 Mar;9(1):25-30. Hum Cell. 1996. PMID: 9183626 Review. Japanese.
Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent.
Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, Hizuta A, Yasuda T, Roth JA, Tanaka N. Ogawa N, et al. Among authors: fujiwara t. Int J Cancer. 1997 Nov 4;73(3):367-70. doi: 10.1002/(sici)1097-0215(19971104)73:3<367::aid-ijc11>3.0.co;2-a. Int J Cancer. 1997. PMID: 9359484
In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer.
Perdomo JA, Naomoto Y, Haisa M, Fujiwara T, Hamada M, Yasuoka Y, Tanaka N. Perdomo JA, et al. Among authors: fujiwara t. J Cancer Res Clin Oncol. 1998 Jan;124(1):10-8. doi: 10.1007/s004320050127. J Cancer Res Clin Oncol. 1998. PMID: 9498829
Contribution of CD95 ligand-induced neutrophil infiltration to the bystander effect in p53 gene therapy for human cancer.
Waku T, Fujiwara T, Shao J, Itoshima T, Murakami T, Kataoka M, Gomi S, Roth JA, Tanaka N. Waku T, et al. Among authors: fujiwara t. J Immunol. 2000 Nov 15;165(10):5884-90. doi: 10.4049/jimmunol.165.10.5884. J Immunol. 2000. PMID: 11067949
4,121 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback